Lookout
VIP Member
- Oct 5, 2007
- 922
- 77
- 63
Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Tuesday, May 26 2009
Clinical Data from Trial of ImmunoCellular Therapeutics' Cancer Vaccine ICT-107 to Be Presented...
LOS ANGELES -- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, today announced that clinical data from the company's Phase 1 trial of cancer vaccine ICT-107, will be presented at the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting taking place May
29 through June 2, 2009 in Orlando, Florida.
Following are the presentation details:
Abstract #2032: "A phase I trial of tumor associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glioblastoma." Poster to be presented in the Central Nervous System Tumors session on May 31, 2009, 8:00 a.m. to 12:00 p.m. EDT (Level 2, West Hall C) by Surasak Phuphanich, MD, FAAN, principal investigator on the trial and neurosurgeon at Cedars Sinai Medical Center.
About ICT-107.............more
Cancer Vaccine Development
Dendritic cell vaccine accelerates CD8+ memory and prime-boost response
September 19th, 2005
"Efficient boosting of memory T-cell numbers to protective levels generally requires a relatively long interval between immunizations. Decreasing this interval could be crucial in biodefense and cancer immunotherapy, in which rapid protective responses are essential. Here, we show that vaccination with peptide-coated dendritic cells (DCs) generated CD8+ T cells with the phenotype and function of memory cells within 4 to 6 days," scientists in the United States report.
"These early memory CD8+ T cells underwent vigorous secondary expansion in response to a.................